ES2525932T3 - Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología - Google Patents

Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología Download PDF

Info

Publication number
ES2525932T3
ES2525932T3 ES07776522.0T ES07776522T ES2525932T3 ES 2525932 T3 ES2525932 T3 ES 2525932T3 ES 07776522 T ES07776522 T ES 07776522T ES 2525932 T3 ES2525932 T3 ES 2525932T3
Authority
ES
Spain
Prior art keywords
radiolabeled
imaging agents
dihydrotetrabenazine
derivatives
dihydrotetrabenazine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07776522.0T
Other languages
English (en)
Inventor
Hank F. Kung
Mei-Ping Kung
Michael Kilbourn
Daniel M. Skovronsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
University of Pennsylvania Penn
Avid Radiopharmaceuticals Inc
Original Assignee
University of Michigan
University of Pennsylvania Penn
Avid Radiopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan, University of Pennsylvania Penn, Avid Radiopharmaceuticals Inc filed Critical University of Michigan
Application granted granted Critical
Publication of ES2525932T3 publication Critical patent/ES2525932T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de fórmula**Fórmula** o una sal farmacéuticamente aceptable del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36

Claims (1)

  1. imagen1
    imagen2
ES07776522.0T 2006-05-02 2007-05-01 Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología Active ES2525932T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79651806P 2006-05-02 2006-05-02
US796518P 2006-05-02
US90811607P 2007-03-26 2007-03-26
US908116P 2007-03-26
PCT/US2007/010478 WO2007130365A2 (en) 2006-05-02 2007-05-01 Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents

Publications (1)

Publication Number Publication Date
ES2525932T3 true ES2525932T3 (es) 2015-01-02

Family

ID=38668238

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07776522.0T Active ES2525932T3 (es) 2006-05-02 2007-05-01 Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología

Country Status (19)

Country Link
US (1) US8562949B2 (es)
EP (2) EP2012833B1 (es)
JP (1) JP5392622B2 (es)
KR (1) KR101429302B1 (es)
CN (1) CN101484190B (es)
AU (1) AU2007248764B2 (es)
BR (1) BRPI0711481A8 (es)
CA (1) CA2650904C (es)
DK (1) DK2012833T3 (es)
ES (1) ES2525932T3 (es)
IL (1) IL195044A (es)
MX (1) MX2008014064A (es)
NO (1) NO341065B1 (es)
PL (1) PL2012833T3 (es)
PT (1) PT2012833E (es)
SI (1) SI2012833T1 (es)
TW (1) TWI432214B (es)
WO (1) WO2007130365A2 (es)
ZA (1) ZA200810200B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897768B2 (en) 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
US7897769B2 (en) 2007-10-25 2011-03-01 General Electric Company Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
CN101998956B (zh) * 2007-10-25 2014-10-22 通用电气公司 氟化二氢丁苯那嗪醚成像剂和探针
US7897770B2 (en) 2007-10-25 2011-03-01 General Electric Company Fluorinated dihydrotetrabenazine ether imaging agents and probes
CA2703563A1 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US7910738B2 (en) 2007-11-29 2011-03-22 General Electric Company Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7919622B2 (en) 2007-12-07 2011-04-05 Kande Kankanamalage Dayarathna Amarasinghe Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
US8013161B1 (en) 2007-12-07 2011-09-06 General Electric Company Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
BRPI0913457B8 (pt) 2008-09-18 2021-08-31 Auspex Pharmaceutical Inc Composto e composição farmacêutica
US20120107239A1 (en) * 2009-03-19 2012-05-03 Nobuya Inagaki Precursor of Molecular Probe for Pancreatic Islet Imaging and Use of the Same
CN102120742B (zh) * 2010-01-08 2013-03-13 中国药科大学 一种丁苯那嗪的制备方法
EP2394668A1 (en) * 2010-06-01 2011-12-14 Julius-Maximilians-Universität Würzburg PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN101985446B (zh) * 2010-06-10 2012-05-30 江苏省原子医学研究所 一种(±)-9-O-去甲基-α-二氢丁苯那嗪合成方法
WO2012121746A2 (en) * 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
CN102260255B (zh) * 2011-07-07 2013-07-10 江苏省原子医学研究所 一种9,10-二甲氧基-1,3,4,6,7,11b-六氢-3-异丁基-2H-苯并[a]喹嗪-2-酮的简便合成方法
NZ705372A (en) 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102936246A (zh) * 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｍａｔ２のベンゾキノロン阻害剤
US20160207917A1 (en) * 2013-09-27 2016-07-21 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016006622A (es) * 2013-11-22 2016-12-09 Auspex Pharmaceuticals Inc Metodos para tratar actividad muscular anormal.
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
AU2015209330A1 (en) 2014-01-27 2016-07-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
EA201791977A1 (ru) 2015-03-06 2018-01-31 Оспекс Фармасьютикалз, Инк. Способы лечения патологических непроизвольных движений
TW201720443A (zh) 2015-10-09 2017-06-16 梯瓦製藥國際有限責任公司 用以治療帕金森氏症之經氘化左旋多巴、碳度巴、以及奧匹卡朋的組合
TW201906818A (zh) * 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
CN108912118A (zh) * 2018-07-12 2018-11-30 新乡学院 一种四氢异喹啉并三嗪骨架化合物及其制备方法
BR112022002107A2 (pt) * 2019-08-12 2022-04-12 Shandong luye pharmaceutical co ltd Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
CN111320620A (zh) * 2020-03-17 2020-06-23 四川大学华西医院 一种异喹啉并哒嗪酮类化合物及其合成方法和应用
WO2022203984A1 (en) 2021-03-22 2022-09-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
CN114288419B (zh) * 2021-12-30 2023-08-18 中山大学附属第八医院（深圳福田） 一种利福平纳米递药系统的制备及其在防治帕金森病方面的应用
CN115536705A (zh) * 2022-09-23 2022-12-30 江苏省原子医学研究所 靶向ii型囊泡单胺转运体分子探针及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053845A (en) 1962-09-11 Benzofykedocolines
DE1470074C3 (de) * 1964-07-25 1974-01-24 Merck Patent Gmbh, 6100 Darmstadt 1,2,3,4,6,7-Hexahydro-l lbH-benzo eckige Klammer auf a eckige Klammer zu chinolizine sowie deren Acetate und/oder phsiologisch verträgliche Säureadditionssalze sowie Verfahren zu ihrer Herstellung
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US5278308A (en) * 1992-02-28 1994-01-11 The Trustees Of The University Of Pennsylvania Iodine derivatives of tetrabenazine
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
NO341065B1 (no) 2017-08-14
IL195044A (en) 2013-08-29
AU2007248764A1 (en) 2007-11-15
TW200810783A (en) 2008-03-01
KR20090007781A (ko) 2009-01-20
KR101429302B1 (ko) 2014-08-11
BRPI0711481A2 (pt) 2011-11-16
CA2650904A1 (en) 2007-11-15
WO2007130365A3 (en) 2008-11-27
CA2650904C (en) 2015-07-07
EP2012833A2 (en) 2009-01-14
WO2007130365A2 (en) 2007-11-15
EP2604290A2 (en) 2013-06-19
CN101484190A (zh) 2009-07-15
EP2012833B1 (en) 2014-10-29
JP2009535403A (ja) 2009-10-01
US20080050312A1 (en) 2008-02-28
ZA200810200B (en) 2012-02-29
CN101484190B (zh) 2011-07-20
EP2604290A3 (en) 2013-07-10
BRPI0711481A8 (pt) 2017-11-28
JP5392622B2 (ja) 2014-01-22
EP2012833A4 (en) 2011-06-29
PT2012833E (pt) 2014-12-23
IL195044A0 (en) 2011-08-01
DK2012833T3 (en) 2015-01-19
MX2008014064A (es) 2009-06-12
SI2012833T1 (sl) 2015-03-31
NO20085004L (no) 2009-02-02
US8562949B2 (en) 2013-10-22
TWI432214B (zh) 2014-04-01
PL2012833T3 (pl) 2015-05-29
AU2007248764B2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
ES2644750T3 (es) Gaviones
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
ES2319679T5 (es) Módulo de perforación de cápsulas
ES2548578T3 (es) Monosebacato de un derivado de pirazol
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
CY1110137T1 (el) Συμπυκνωμενες τρικυκλικες ενωσεις peri χρησιμες ως αντιβακτηριακοι παραγοντες
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
HRP20090017T3 (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
CR9587A (es) Derivados de piridazina
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
FI20065267A (fi) Järjestely dentaalikuvausta varten
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ES2390396T7 (es) Procedimiento de preparación de compuestos p-hidroximandélicos eventualmente sustituidos y derivados